This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by Applied Genetic Technologies Corp
Sponsor:
Collaborator:
National Eye Institute (NEI)
Information provided by (Responsible Party):
Applied Genetic Technologies Corp
ClinicalTrials.gov Identifier:
NCT02599922
First received: November 5, 2015
Last updated: June 27, 2017
Last verified: June 2017
  Purpose
This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of rAAV2tYF-PR1.7-hCNGB3 administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGB3 gene. The primary study endpoint will be safety and the secondary study endpoint will be efficacy.

Condition Intervention Phase
Achromatopsia Biological: rAAV2tYF-PR1.7-hCNGB3 Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene

Resource links provided by NLM:


Further study details as provided by Applied Genetic Technologies Corp:

Primary Outcome Measures:
  • Adverse events [ Time Frame: 1 year ]
    Proportion of participants experiencing grade 3 or greater adverse events


Secondary Outcome Measures:
  • Visual acuity [ Time Frame: 1 year ]
    Changes in best corrected visual acuity compared to pre-treatment

  • Light aversion [ Time Frame: 1 year ]
    Changes in light discomfort testing compared to pre-treatment

  • Color vision [ Time Frame: 1 year ]
    Changes in color vision testing compared to pre-treatment


Estimated Enrollment: 24
Study Start Date: February 2016
Estimated Study Completion Date: December 2022
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lower dose
rAAV2tYF-PR1/7-hCNGB3 will be administered at the lowest of three planned dose levels.
Biological: rAAV2tYF-PR1.7-hCNGB3
rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
Experimental: Middle dose
rAAV2tYF-PR1/7-hCNGB3 will be administered at the middle of three planned dose levels.
Biological: rAAV2tYF-PR1.7-hCNGB3
rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
Experimental: Higher dose
rAAV2tYF-PR1/7-hCNGB3 will be administered at the highest of three planned dose levels.
Biological: rAAV2tYF-PR1.7-hCNGB3
rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
Experimental: Maximum tolerated dose
rAAV2tYF-PR1/7-hCNGB3 will be administered at the maximum tolerated dose identified from Groups 1, 2 and 3.
Biological: rAAV2tYF-PR1.7-hCNGB3
rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.

Detailed Description:

This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of rAAV2tYF-PR1.7-hCNGB3 administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGB3 gene. The primary study endpoint will be safety and the secondary study endpoint will be efficacy.

Subjects will be enrolled sequentially in four groups. Subjects in Groups 1, 2 and 3 will be at least 18 years of age and will receive a lower, middle or higher dose of study agent. Subjects in Group 4 will be at least 6 years of age and will receive the maximum tolerated dose identified in Groups 1, 2 and 3.

Safety will be monitored by evaluation of ocular and non ocular adverse events and hematology and clinical chemistry parameters. Efficacy parameters will include visual acuity, light discomfort testing, color vision, static visual field, ERG, adaptive optics retinal imaging and OCT.

  Eligibility

Ages Eligible for Study:   6 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria include:

  1. Retinal disease consistent with a diagnosis of achromatopsia and documented mutations in both alleles of the CNGB3 gene;
  2. At least 18 years of age for Groups 1, 2 and 3 and at least 6 years of age for Group 4;
  3. Able to perform tests of visual and retinal function;
  4. Visual acuity in the study eye not better than 55 ETDRS letters (Snellen equivalent 20/80) based on the average of two examinations at the baseline visit;
  5. Acceptable laboratory parameters;
  6. For females of childbearing potential: A negative pregnancy test within 2 days before administration of study agent.

Exclusion Criteria include:

  1. Refractive error of ≥ -8.00 diopters (spherical equivalent) of myopia in the study eye;
  2. Evidence of degenerative myopia regardless of the refractive error in the study eye;
  3. Pre-existing eye conditions that would contribute to vision loss in either eye or increase the risk of subretinal injection in the study eye.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02599922

Contacts
Contact: Jill Dolgin, PharmD advocacy@agtc.com

Locations
United States, Florida
VitreoRetinal Associates Recruiting
Gainesville, Florida, United States, 32607
Bascom Palmer Eye Institute Recruiting
Miami, Florida, United States, 33136
United States, Illinois
Pangere Center for Inherited Retinal Diseases, The Chicago Lighthouse for People Who Are Blind or Visually Imp Recruiting
Chicago, Illinois, United States, 60608
United States, Oregon
Casey Eye Institute, Oregon Health and Sciences University Recruiting
Portland, Oregon, United States, 97239
United States, Wisconsin
Medical College of Wisconsin Active, not recruiting
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
Applied Genetic Technologies Corp
National Eye Institute (NEI)
Investigators
Study Director: Mike Goldstein, MD Applied Genetics Technologies Corporation
  More Information

Additional Information:
Publications:
Responsible Party: Applied Genetic Technologies Corp
ClinicalTrials.gov Identifier: NCT02599922     History of Changes
Other Study ID Numbers: AGTC_CNGB3-001
R24EY022023 ( U.S. NIH Grant/Contract )
Study First Received: November 5, 2015
Last Updated: June 27, 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Color Vision Defects
Vision Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Eye Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on August 17, 2017